Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA.
CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA.
CAPLYTA is the only U.S. Food and Drug Administration (FDA) approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate.
Our LytaLink patient and prescriber support program continues to be very effective in supporting patient access to CAPLYTA.